Diego Kauffmann‐Guerrero

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

Melanie Janning, Juliane Süptitz, Corinna Albers et al. · Annals of Oncology · 2022 · 87 citations · Full text

Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy

Jan Leipe, Lisa Christ, Andreas Arnoldi et al. · RMD Open · 2018 · 85 citations · Full text

Disease Burden, Immunology, Checkpoint Inhibitor Therapy +20

Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

Diego Kauffmann‐Guerrero, Kathrin Kahnert, Rosemarie Kiefl et al. · Scientific Reports · 2021 · 65 citations · Full text

Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

Felix Carl Saalfeld, Carina Wenzel, Petros Christopoulos et al. · Journal of Thoracic Oncology · 2021 · 58 citations · Full text

Medicine, Immunology, Immune Checkpoint Inhibitor +6

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Nikolaj Frost, Petros Christopoulos, Diego Kauffmann‐Guerrero et al. · Therapeutic Advances in Medical Oncology · 2021 · 47 citations · Full text